Research

In this report from Budapest, Hungary, the authors compared several clinical features (including time parameters, rate of intravenous thrombolysis and endovascular therapies) of patients admitted to a university stroke-unit within a 2-month COVID-pandemic period (March and April of 2020) with an identical pre-COVID period of 2019.

For September 2020, we have selected: The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report.

For September 2020, we have selected two complementary papers.

Evaluating blood pressure and heart rate changes upon standing helps screening for nOH at bedside.

A paper has just been published – Collaboration between palliative care and neurology: a survey of clinicians in Europe.

Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients

New-onset seizures in the context of SARS-CoV-2 infection

Epilepsy care during the COVID-19 pandemic

Disability through COVID-19 pandemic: Neurorehabilitation cannot wait

Here are the news from the Coma and Disorders of Consciousness panel for May and June, including feedback from the Virtual EAN Congress, new diagnostic and prognostic tools, personalized pain assessment methods and epidemiological data on dysphagia.

For August 2020, we have selected Turner R.S. et al. “Nilotinib Effects on Safety, Tolerability,and Biomarkers in Alzheimer’s Disease” Annals of Neurology 2020;88:183–194. doi: 10.1002/ana.25775. Epub 2020 May 28.

For August 2020, we have selected Rogers J.P. et al. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic” Lancet Psychiatry 2020; 7:611-627.

This Guideline addresses a number of medical issues which neurologists and other medical doctors who are involved in the medical management of patients with dementia are confronted with on a regular basis.

In this study recently published in Brain, the authors collected detailed clinical and paraclinical data from patients with suspected COVID-19-related neurological disorders in whom the diagnosis of COVID-19 was confirmed through RNA PCR, or where the diagnosis was probable/possible according to World Health Organisation criteria.

In this research letter recently published in JAMA, the authors assessed persistent symptoms in patients who had been discharged from hospital after recovery from COVID-19.